Human herpesvirus-6 infection in solid organ and stem cell transplant recipients.
HHV-6 has in recent years become recognized as a potential significant pathogen in both solid organ and stem cell transplant recipients. HHV-6 infections are common after transplantation regardless of the utilized diagnostic technique. Several different clinical manifestations have been described including fever, bone marrow suppression, encephalitis, skin rash, and hepatitis. The most important end-organ disease is encephalitis in stem cell transplant recipients that has been reported to have a mortality of at least 40%. HHV-6 is also considered an immunomodulatory and immunosuppressive virus that may facilitate super-infections with other opportunistic pathogens such as CMV and fungal infections and thereby contribute to overall mortality. No established therapy exists but both ganciclovir and foscarnet have been reported to have in vitro and in vivo efficacy against HHV-6.
Ljungman
Per
P
Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden. per.ljungman@medhs.ki.se
Singh
Nina
N
D015654:Herpesvirus 6, Human / Q000302:isolation & purification*; D006801:Humans; D016377:Organ Transplantation; D019349:Roseolovirus Infections / Q000188:drug therapy / Q000453:epidemiology / Q000503:physiopathology* / Q000517:prevention & control; D033581:Stem Cell Transplantation; D013548:Sweden